View Item 

Show simple item record

Clinical markers for identifying cholinergic deficits in Parkinson's disease
dc.contributor.authorMüller, Martijn L.t.m.en_US
dc.contributor.authorBohnen, Nicolaas I.en_US
dc.contributor.authorKotagal, Vikasen_US
dc.contributor.authorScott, Peter J.H.en_US
dc.contributor.authorKoeppe, Robert A.en_US
dc.contributor.authorFrey, Kirk A.en_US
dc.contributor.authorAlbin, Roger L.en_US
dc.date.accessioned2015-03-05T18:24:38Z
dc.date.available2016-04-01T15:21:07Zen
dc.date.issued2015-02en_US
dc.identifier.citationMüller, Martijn L.t.m. ; Bohnen, Nicolaas I.; Kotagal, Vikas; Scott, Peter J.H.; Koeppe, Robert A.; Frey, Kirk A.; Albin, Roger L. (2015). "Clinical markers for identifying cholinergic deficits in Parkinson's disease." Movement Disorders 30(2): 269-273.en_US
dc.identifier.issn0885-3185en_US
dc.identifier.issn1531-8257en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110743
dc.description.abstractBackgroundCholinergic projection systems degeneration is associated with dopamine nonresponsive features of Parkinson's disease (PD). Cholinergic deficits are variable in nondemented PD. Identification of cholinergic deficits in PD may help with selection of suitable patients for targeted cholinergic drug treatment in PD. The objective of this retrospective multivariate predictor analysis study was to identify clinical markers indicative of cholinergic deficits in PD patients, as assessed by acetylcholinesterase ([11C]PMP) positron emission tomography.MethodsOne hundred thirty‐seven PD patients (34 female) participated; median modified Hoehn and Yahr score was 2.5 (range, 1‐4), average age 65.6 ± 7.4 years, and average duration of motor disease symptoms of 6.0 ± 4.2 years. Subjects were dichotomized as “normocholinergic” or “hypocholinergic” based on a 5th percentile cutoff from normal for the basal forebrain‐cortical and pedunculopontine nucleus‐thalamic cholinergic projection systems. Previously identified clinical indices of cholinergic denervation were used for statistical prediction of cholinergic deficits. Logistic regression determined which risk factors predicted cholinergic deficits. Sensitivity, specificity, and accuracy were determined for the (combinations of) significant predictor variables.ResultsForty‐nine (35.8%) hypocholinergic PD subjects were identified. The combination of rapid eye movement (REM) sleep behavior disorder (RBD) symptoms and fall history showed highest diagnostic accuracy (81.1%) for predicting combined thalamic and cortical cholinergic deficits. A combined assessment of 8.5 m walk time and lower score on the Montreal cognitive assessment scale provided diagnostic accuracy of 80.7% for predicting isolated cortical cholinergic denervation.ConclusionAssessment of clinical indices of cholinergic denervation may be useful for identifying suitable subjects for trials of targeted cholinergic drug treatments in PD. © 2014 International Parkinson and Movement Disorder Societyen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otheracetylcholineen_US
dc.subject.otherPETen_US
dc.subject.otherParkinson's diseaseen_US
dc.subject.otheracetylcholinesteraseen_US
dc.subject.otherbiomarkersen_US
dc.titleClinical markers for identifying cholinergic deficits in Parkinson's diseaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110743/1/mds26061.pdf
dc.identifier.doi10.1002/mds.26061en_US
dc.identifier.sourceMovement Disordersen_US
dc.identifier.citedreferenceNasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695 – 699.en_US
dc.identifier.citedreferenceChung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75: 1263 – 1269.en_US
dc.identifier.citedreferenceBohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009; 73: 1670 – 1676.en_US
dc.identifier.citedreferenceBohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 2013; 81: 1611 – 1616.en_US
dc.identifier.citedreferenceKotagal V, Albin RL, Muller ML, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 2012; 71: 560 – 568.en_US
dc.identifier.citedreferenceBohnen NI, Muller ML. In vivo neurochemical imaging of olfactory dysfunction in Parkinson's disease. J Neural Transm 2013; 120: 571 – 576.en_US
dc.identifier.citedreferenceKotagal V, Albin RL, Muller ML, Koeppe RA, Frey KA, Bohnen NI. Gender differences in cholinergic and dopaminergic deficits in Parkinson disease. J Neural Transm 2013; 120: 1421 – 1424.en_US
dc.identifier.citedreferenceGoetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19: 1020 – 1028.en_US
dc.identifier.citedreferenceHoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427 – 442.en_US
dc.identifier.citedreferenceHughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico‐pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181 – 184.en_US
dc.identifier.citedreferenceBohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006; 26: 1198 – 1212.en_US
dc.identifier.citedreferenceDoty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984; 32: 489 – 502.en_US
dc.identifier.citedreferenceDoty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984; 94: 176 – 178.en_US
dc.identifier.citedreferenceBoeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011; 12: 445 – 453.en_US
dc.identifier.citedreferenceMuller ML, Albin RL, Kotagal V, et al. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. Brain 2013; 136: 3282 – 3289.en_US
dc.identifier.citedreferenceShao X, Hoareau R, Runkle AC, et al. Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [ 11 C]‐labeled radiopharmaceuticals using a Tracerlab FXC‐Pro. J Label Compd Radiopharm 2011; 54: 819 – 838.en_US
dc.identifier.citedreferenceNagatsuka Si S, Fukushi K, Shinotoh H, et al. Kinetic analysis of [ 11 C]MP4A using a high‐radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab 2001; 21: 1354 – 1366.en_US
dc.identifier.citedreferenceBraak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197 – 211.en_US
dc.identifier.citedreferenceSohn YH, Kim JS. The influence of white matter hyperintensities on the clinical features of Parkinson's disease. Yonsei Med J 1998; 39: 50 – 55.en_US
dc.identifier.citedreferenceKotagal V, Albin RL, Muller ML, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 2013; 19: 522 – 526.en_US
dc.identifier.citedreferenceKotagal V, Albin RL, Muller ML, Koeppe RA, Frey KA, Bohnen NI. Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 2014; 82: 1514 – 1520.en_US
dc.identifier.citedreferenceLee SJ, Kim JS, Yoo JY, et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010; 24: 227 – 233.en_US
dc.identifier.citedreferenceMuller ML, Frey KA, Petrou M, et al. β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013; 28: 296 – 301.en_US
dc.identifier.citedreferenceGrimbergen YA, Langston JW, Roos RA, Bloem BR. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 2009; 9: 279 – 290.en_US
dc.identifier.citedreferenceLangston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591 – 596.en_US
dc.identifier.citedreferenceMuller ML, Bohnen NI. Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep 2013; 13: 377.en_US
dc.identifier.citedreferenceSvenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012; 11: 697 – 707.en_US
dc.identifier.citedreferenceDubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y. Cholinergic‐dependent cognitive deficits in Parkinson's disease. Ann Neurol 1987; 22: 26 – 30.en_US
dc.identifier.citedreferenceBohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253: 242 – 247.en_US
dc.identifier.citedreferenceBohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010; 133: 1747 – 1754.en_US
dc.identifier.citedreferenceBohnen NI, Muller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012; 32: 1609 – 1617.en_US
dc.identifier.citedreferenceYarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord 2011; 26: 2496 – 2503.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mds26061.pdf
Size:
623.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.